Growth hormone treatment of children with short stature secondary to intra-uterine growth retardation: effect of 2 years' treatment and 2 years' follow-up.
Growth hormone (GH) treatment has been proposed to improve final height in patients with short stature associated with intra-uterine growth retardation (IUGR). In this study, 30 prepubertal patients aged 9.5 +/- 0.9 years with IUGR and normal GH secretion on pharmacological testing were treated with GH. These patients had a mean birth length of -3.11 +/- 0.80 SDS, and mean growth retardation of -2.58 +/- 0.49 SDS for chronological age. GH, 1.4 IU/kg/week (= 0.07 mg/kg/day), was given for 2 years. Height gain (calculated as the difference of height SDS at baseline and after 2 years) was 1.3 +/- 0.4 SD and was not significantly correlated with height SDS or growth velocity at baseline. These data confirm that 2 years of recombinant human GH treatment increases height gain in patients with IUGR. Two years after treatment interruption, mean gain was maintained at +1.08 SDS and 83% of the children had normal height.
Rosilio
M
M
Laboratoires Lilly France, Saint Cloud, France. MYRIAM_ROSILIO@LILLY.COM
Carel
J C
JC
Blazy
D
D
Chaussain
J L
JL
D000365:Age Determination by Skeleton; D001827:Body Height; D002648:Child; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood / Q000628:therapy*; D005500:Follow-Up Studies; D019382:Human Growth Hormone / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D008297:Male; D013997:Time Factors
D019382:Human Growth Hormone